ArriVent BioPharma, Inc. AVBP Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|
| $45.54M-38.7% | $74.29M-50.6% | $150.39M— | ||
| $267.28M+84.9% | $144.57M— | —— | ||
| $65.2M+73.5% | $37.59M+852% | $3.95M— | ||
| $332.9M+46.7% | $226.98M+41.9% | $159.97M— | ||
| $13K-91.6% | $154K-47.1% | $291K— | ||
| $190K+50.8% | $126K+17.8% | $107K— | ||
| $333.17M+21.2% | $274.94M+68.6% | $163.1M— | ||
| $5.93M+56.9% | $3.78M-16.5% | $4.53M— | ||
| $20M+50.0% | $13.33M+91.7% | $6.95M— | ||
| $14K-91.4% | $162K+15.7% | $140K— | ||
| $25.95M+50.2% | $17.27M+48.6% | $11.62M— | ||
| —— | $14K-92.1% | $177K— | ||
| $25.95M+50.1% | $17.29M+46.5% | $11.8M— | ||
| $4K+33.3% | $3K— | —— | ||
| $711.85M+43.5% | $496.2M+10,566% | $4.65M— | ||
| -$404.64M-69.8% | -$238.33M-51.0% | -$157.85M— | ||
| $14K+107% | -$211K— | —— | ||
| $307.22M+19.2% | $257.65M+268% | -$153.19M-80.0% | ||
| $333.17M+21.2% | $274.94M+68.6% | $163.1M— | ||
| $190K+50.8% | $126K+17.8% | $107K— | ||
| $13K-91.6% | $154K-47.1% | $291K— | ||
| $69K— | —— | $2.73M— | ||
| $13K-91.6% | $154K-47.1% | $291K— | ||
| $190K+50.8% | $126K+17.8% | $107K— | ||
| $267.28M+84.9% | $144.57M— | —— | ||
| $13K-91.6% | $154K-47.1% | $291K— | ||
| $190K+50.8% | $126K+17.8% | $107K— | ||
| $20M+50.0% | $13.33M+91.7% | $6.95M— | ||
| $20M+50.0% | $13.33M+91.7% | $6.95M— | ||
| $14K-92.0% | $176K-44.5% | $317K— | ||
| $4K+33.3% | $3K— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are ArriVent BioPharma, Inc.'s total assets?
- ArriVent BioPharma, Inc. (AVBP) holds $349.3M in total assets, up 62.1% year over year.
- How much debt does ArriVent BioPharma, Inc. have?
- ArriVent BioPharma, Inc. carries $419.0K in total debt against $324.0M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does ArriVent BioPharma, Inc. have?
- ArriVent BioPharma, Inc. holds $62.1M in cash and equivalents.
- Can ArriVent BioPharma, Inc. cover its short-term obligations?
- Its current ratio is 13.95 — current assets exceed current liabilities.
- Where does ArriVent BioPharma, Inc.'s balance sheet data come from?
- Every line is extracted from ArriVent BioPharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.